55413-89-3

Upstream product

• 142-84-7 di-n-propylamine 
• 55414-52-3 4'-acetylamino-3'-bromomethyl-acetophenone 
• 40664-73-1 4'-acetylamino-3'-methyl-acetophenone 
• 109-89-7 diethylamine 

Downstream Products

• 97776-08-4 4'-amino-3'-diethylaminomethyl-acetophenone 
• 56340-02-4 1-(4-Amino-3-diethylaminomethyl-phenyl)-2-tert-butylamino-ethanol 
• 56341-00-5 1-(4-Amino-3-bromo-5-diethylaminomethyl-phenyl)-2-tert-butylamino-ethanone 
• 56340-99-9 1-(4-Amino-3-bromo-5-diethylaminomethyl-phenyl)-2-tert-butylamino-ethanol 
• 56340-03-5 N-[4-(2-tert-Butylamino-1-hydroxy-ethyl)-2-diethylaminomethyl-phenyl]-acetamide 
• 97760-86-6 4'-amino-3'-bromo-5'-diethylaminomethyl-acetophenone 

Relevant academic research and scientific papers

Synthesis of further amino-halogen-substituted phenyl-aminoethanols

Starting from clenbuterol as a lead structure, new 4-amino-phenyl-aminoethanol analogues have been synthesized by different approaches. In these compounds one or both of the chlorine atoms of clenbuterol are replaced by other residues. This has led to compounds with high intrinsic β2-mimetic and/or β1-blocking activities. 1-(4-Amino-3-chloro-5-trifluoromethyl-phenyl)-2-tert.-butylamino-ethanol hydrochloride (mabuterol) has been selected for clinical development. A detailed description is also given of the syntheses of new intermediate acetophenone derivatives as well as of the resolution of mabuterol into its enantiomers.

Aminobenzyl-amines and salts thereof

Compounds of the formula STR1 wherein R1 is hydrogen or aliphatic or aromatic carboxylic acyl, R2 is hydrogen, chlorine or bromine, R3 is fluorine, alkyl of 1 to 4 carbon atoms, trifluoromethyl, cyano, carbamoyl, carboxyl,

Aminobenzyl-amides and salts thereof

Compounds of the formula SPC1 Wherein R1 is hydrogen or aliphatic or aromatic carboxylic acyl, R2 is hydrogen, chlorine or bromine, R3 is fluorine, alkyl of 1 to 4 carbon atoms, trifluoromethyl, cyano, carbamoyl, carboxyl,